Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05945524
Recruiting Not applicable

Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination

NCT05945524 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Toulouse
Phase
Not applicable
Started
2023-09-28
Last updated
2025-04-10

Condition(s) studied

Multiple Myeloma

Investigational drug(s) / intervention(s)

Bone marrow sampling

Bone marrow sampling: Bone marrow sampling collected at 12 weeks after initiation treatment (day 1 cycle 4)

Study summary

The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * With multiple myeloma * Who receive Teclistamab * Consent form signed Exclusion Criteria: * Patient under legal protection

Primary outcome measure(s)

  • Response to teclistamab at 12 weeks — at day 1 Cycle 4 (each cycle is 28 days)
    response according to International Myeloma Working Group criteria

Trial sites (18)

FacilityCityRegionStatus
CHU d'Amiens Amiens France Recruiting
CHU de Caen Caen France Recruiting
Polyclinique du Parc Drevon Dijon France Recruiting
CH Annecy Genevois Epagny Metz- Tessy France Recruiting
CHU de Lille Lille France Recruiting
Centre Léon Bérard Lyon France Recruiting
CHU de Montpellier Montpellier France Recruiting
Hôpital Saint-Louis Paris France Recruiting
Hôpital Saint-Antoine Paris France Recruiting
Hôpital Necker Paris France Recruiting
CHU de Bordeaux Pessac France Recruiting
CHU de Lyon Pierre-Bénite France Recruiting
CHU de Poitiers Poitiers France Recruiting
CHU de Rennes Rennes France Recruiting
CH Saint-Etienne Saint-Priest-en-Jarez France Recruiting
CHU de Toulouse Toulouse France Recruiting
CHU de Tours Tours France Recruiting
CHRU Nancy Vandœuvre-lès-Nancy France Recruiting

More University Hospital, Toulouse trials in France

Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Osteogenesis Imperfecta Recruiting
Autistic Symptomatology and Sensory Profile in Children With Prader-Willi Syndrome Recruiting
Impact of VARIation of OXYdo-reduction Potential in Cardiac Surgery on Post-operative Outcome Recruiting
Use of a New Diagnostic Tool in the Detection and Characterization of Endometriosis Lesions Recruiting
Use of a Social Assistance Robot in a Population of Children Subjected to Prolonged Isolation Recruiting

Other trials for the same condition

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma Active, not recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) Recruiting
Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation. Recruiting
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma Active, not recruiting
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05945524 on ClinicalTrials.gov ↗ ← All trials in France